596 KB39 KB199220252000Bohuslavizki, Karl H.Buchert, RalphClausen, MalteJenicke, LarsKlutmann, SusanneKröger, SabineMester, Janosletnik:34številka:4str. 337-347COBISSID:12585945ISSN:1318-2099URN:URN:NBN:SI:doc-DTCN3G38enCroatian Medical Association - Croatian Society of RadiologySlovenian Medical Society - Section of RadiologyRadiology and oncology (Ljubljana)amifostinAmifostineBone marrowBone neoplasmsDisease models, animalErythrocyte countErythrocyte indiceskostni mozegonkologijaPlatelet countpreventivna medicinaRabbitsRadiation effectsRadiation-protective agentsradiologijaRadionuclide imagingRheniumSecondaryTherapeutic usezdravljenjeBone marrow protection by amifostine in Re-186-HEDP treatment| first results obtained in a rabbit animal model| prvi rezultati na živalskem modelu| Zaščita kostnega mozga z amifostinom pri zdravljenju z Re-186-HEDP|Background. in the last years various reports dealt with radioprotective effects of amifostine (Ethyol, USB, Philadelphia, PA). Since amifostine is markedly accumulated in bone marrow it looks worthwhile to study the radioprotective effects of amifostine on bone marrow in patients treated with Re-186-HEDP. As a first step animal studies were performed using New Zealand White rabbits. Materials and methods. A total of 18 rabbits received 300 MBq Tc-99m-HDP for whole-body scintigraphy. Thereafter, 9 animals were treated with 200 mg/kg body weight amifostine, and 9 rabbits served as controls receiving physiological saline solution. Then, these 18 rabbits received 400 MBq Re-186-HEDP i.v. Two rabbits served as untreated controls and received neither Tc-99m-HDP nor Re-186 HEDP. Blood samples were taken at the beginning and in two-week-intervals for the duration of two months in all 20 animals. Laboratory findings were determined for white and red blood cells, for platelet count and for hemoglobin. Two months after therapy all animals were sacrificed, and both femora were removed surgically for histopathological examination of bone marrow. Results. In controls as well as in amifostine-treated animals, the red blood cell count and the hemoglobin were almost constant at all times of observation. In 9 control rabbits the mean platelet count was 265.22+-127.41 Mrd/1 prior to Re-186-HEDP-therapy. Two weeks after therapy the mean platelet count was reduced to 211.22+-52.8 Mrd/1.Prior to Re-186-HEDP-therapy the mean platelet count of amifostine-treated rabbits was not significantly different (p.0.05) from control rabbits. Two weeks after injection of the radionuclide the mean platelet count decreased to 180.67+-37.43 Mrd/1 in the amifostine group (Abstract truncated at 2000 characters.)V zadnjih nekaj letih poročajo o radioprotektivnem delovanju amifostina (Etyhol, USB, Philadelphia, PA). Ker se amifostin znatno kopiči v kostnem mozgu, se zdi zelo primeren za proučevanje radioprotektivnega učinka na kostnimozeg pri bolnikih, ki so zdravljeni z Re-186-HEDP. Narejene so že začetne raziskave na živalih, uporabili so novozelandske bele zajce. Material in metode. 18 zajcem smo naredili scintigrafijo celotnega telesa s TC-99m-HDP,ki so ob tej preiskavi prejeli 300 MBq. 9 živali smo nato zdravili z amifostinom v odmerku 200 mg/kg telesne teže, 9 zajcev pa je služilo za kontrolno skupino in smo jim dali le fiziološko raztopino. Vsem 18 zajcem smo nato aplicirali 400 MBq Re-186-HEDP i.v. Dva zajca pa nista prejela ne Tc-99m-HDP ne Re-186-HEDP, ker smo ju že na začetku raziskave določili - ob omenjeni kontrolni skupini - za netretirana kontrolna primera. Krvne preiskavesmo naredili na začetku raziskave in jih ponavljali dva meseca v dvotedenskih intervalih pri vseh 20 živalih. Določali smo levkocite, eritrocite, trombocite in hemoglobin. Dva meseca po zdravljenju smo vse živaližrtvovali in jim kirurško odstranili femurje zaradi histopatološke preiskave kostnega mozga. Rezultati. V obeh netretiranih kontrolnih živalih inv živalih, ki so prejele amifostin so bili eritrociti in hemoglobin skoraj nespremenjeni ves čas opazovanja. Pri 9 kontrolnih živalih, ki niso prejele amifostina, je bila srednja vrednost trombocitov pred apikacijo RE-186-HEDP 265.22+-127.41 x 10/l. Dva tedna po aplikaciji omenjenega radiofarmaka je bilasrednja vrednost trombocitov znižana na 211.22+-52.8 x 10/l. Pri živalih, ki so prejele amifostin in pri tistih, ki ga niso, se pred zdravljenjem z Re -186-HEDP srednje vrednosti trombocitov niso bistveno razlikovale (p >0.05). (Izvleček prekinjen pri 2000 znakih.)TEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaOnkološki inštitut Ljubljana